Jonathan Van-Tam on COVID’s Next Phase - Summary - MDSpire

Jonathan Van-Tam on COVID’s Next Phase

Former UK Deputy Chief Medical Officer discusses new protein-based vaccines, declining uptake, and the ongoing risks of COVID-19

  • By

  • James Strachan

  • Julian Upton

  • April 14, 2026

  • 7 min

Share

Objective:

To discuss the current landscape of COVID-19 prevention and the introduction of Sanofi's Nuvaxovid vaccine in the UK, particularly focusing on its implications for public health and vaccine hesitancy.

Approach:
    Key Findings:
    • COVID-19's lethality has returned to levels similar to seasonal flu, but it remains a public health concern.
    • The introduction of Nuvaxovid provides a non-mRNA vaccine option, which may address some vaccine hesitancy.
    • Diverse vaccine technologies are crucial for effective pandemic response and future immunization strategies.
    Interpretation:

    COVID-19 continues to pose a significant health risk, comparable to seasonal flu, necessitating ongoing vaccination efforts and the introduction of varied vaccine technologies.

    Limitations:
    • The article does not provide specific data on the effectiveness of Nuvaxovid compared to existing vaccines.
    • No direct evidence is presented regarding the impact of alternating vaccine types on immunity.
    • Lack of data on public perception and hesitancy towards Nuvaxovid and mRNA vaccines.
    Conclusion:

    The introduction of Nuvaxovid into the UK vaccination program represents a strategic move to enhance public health responses to COVID-19, while also addressing vaccine hesitancy and ensuring a diverse vaccine portfolio.

Original Source(s)

Jonathan Van-Tam on COVID’s Next Phase

  • by James Strachan, Julian Upton

  • April 14, 2026

Related Content

Self-Sampling Shows Test Agreement

The study authors frame the device as a potential way to simplify screening, while emphasizing that larger validation studies are still needed.

Recent COVID-19 Shot Linked to Less Spread

Protection against spread appeared strongest within 6 months of vaccination, while exposed vaccinated contacts showed no measurable reduction in infection risk.

31 Live Births Reported Following Uterus Transplant

Single-center series details maternal, obstetric, and neonatal outcomes among recipients with uterine-factor infertility